Skip to main content
SpringerLink
Log in

Brentuximab vedotin use in a jaundiced case with resistant Hodgkin lymphoma

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

A Correction to this article was published on 03 June 2019

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Change history

  • 03 June 2019

    The original version of this article contained a mistake in one of the author names. Cem Irili should have been Cem Mirili.

  • 03 June 2019

    The original version of this article contained a mistake in one of the author names. Cem Irili should have been Cem Mirili.

References

  1. Gualberto A (2012) Brentuximab vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. Expert Opin In Drugs 21:205–216

    Article  CAS  Google Scholar 

  2. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R (2012) Results of pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 30:2183–2189

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  3. Gibb A, Jones C, Bloor A, Kulkarni S, Illidge T, Linton K, Radford J (2013) Brentuximab vedotin in refractoy CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a named patient programme at a single UK center. Haematologica 98:611–614

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  4. Zinzani PL, Viviani S, Anastasia A, Vitolo U, Luminari S, Zaja F, Corradini P, Spina M, Brusamolino E, Gianni AM, Santoro A, Botto B, Derenzini E, Pellegrini C, Argnani L (2013) brentuximab vedotin İN relapsed or refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica 98:1232–1236

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Gopal AK, Chen R, Smith SE, Ansell AM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Chi X, Sievers EL, Younes A (2015) Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood 125:1236–1243

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. Salihoglu A, Elverdi T, Karadogan I, Paydas S, Ozdemir E, Erdem G, Karadurmus N, Akyol G, Kaynar L, Yegin Z, Sucak G, Ozkocaman V, Topcuoglu P, Ozcan M, Birtas E, Goker H, Baslar Z, Ferhanoglu B (2015) Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. Ann Hematol 94:415–420

    Article  PubMed  CAS  PubMed Central  Google Scholar 

Download references

Conflict of Interest

The authors declare that they have no conflict of interest.

Informed Consent

Informed consent has been taken from patient and his relatives.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Cukurova University Faculty of Medicine, Balcali, Adana, Turkey

    Semra Paydas, Ali Ogul, Cem Irili & Serkan Gokcay

Authors
  1. Semra Paydas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ali Ogul
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cem Irili
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Serkan Gokcay
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Semra Paydas.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Paydas, S., Ogul, A., Irili, C. et al. Brentuximab vedotin use in a jaundiced case with resistant Hodgkin lymphoma. Ann Hematol 95, 145–146 (2016). https://doi.org/10.1007/s00277-015-2493-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-015-2493-x

Keywords

Search

Navigation